Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
MSD, a unit of U.S. drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs in India. Global pharmaceutical firms have had a series of patent disputes with Indian makers of generic drugs and several recent Indian rulings have gone against the international giants. MSD holds an Indian patent on sitagliptin, a chemical compound sold under the Januvia and Janumet brands used to treat type-2 diabetes.
Help employers find you! Check out all the jobs and post your resume.
MSD, a unit of U.S. drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs in India. Global pharmaceutical firms have had a series of patent disputes with Indian makers of generic drugs and several recent Indian rulings have gone against the international giants. MSD holds an Indian patent on sitagliptin, a chemical compound sold under the Januvia and Janumet brands used to treat type-2 diabetes.
Help employers find you! Check out all the jobs and post your resume.
